← Patent-cliff monitor small molecule GATTEX KIT TEDUGLUTIDE
Loss of exclusivity May 2026 FDA regulatory exclusivity expiry
Company TAKEDA PHARMACEUTICALS USA INC
Drug detail Brand name GATTEX KIT Active ingredient TEDUGLUTIDE Strength 5MG/VIAL Dosage form POWDER Route SUBCUTANEOUS Modality Small molecule FDA approval December 2012 Marketing status RX
Listed patents Patent Expires Type 7847061*PED May 2026 — 9060992*PED May 2026 — 9060992 November 2025 use U-1320 7847061 November 2025 use U-1320
Regulatory exclusivity Code Expires ODE-240 May 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.